

## High Altitude Polycythemia Presenting as Atypical Chest Pain with TMT Positive and Normal Coronaries

DR N N Anand<sup>1</sup>, DR Karthikeya TM<sup>2</sup>, DR Divya Sriramulu<sup>3</sup>

<sup>1</sup> Professor & HOD, Department of general medicine, Sree Balaji Medical College and Hospital, Chromepet, Tamil Nadu, India. [dmaganand1971@gmail.com](mailto:dmaganand1971@gmail.com)

<sup>2</sup> Assistant Professor, Department of general medicine, Sree Balaji Medical College and Hospital, Chromepet, Tamil Nadu, India.

<sup>3</sup> Senior resident, Department of general medicine, Sree Balaji Medical College and Hospital, Chromepet, Tamil Nadu, India.

### KEYWORDS

high altitude, polycythemia, ischemia, chestpain, TMT, phlebotomy, coronaries

### ABSTRACT

High-altitude polycythemia (HAP), also known as chronic mountain sickness (CMS), is a condition in which individuals residing at high altitudes develop increased red blood cell mass in response to chronic hypoxia. This leads to increased hemoglobin and hematocrit levels, which can result in complications such as blood hyperviscosity, thrombotic events, and rarely, cardiovascular symptoms like chest pain. This case report illustrates a patient presenting with atypical chest pain, a positive treadmill test (TMT), and normal coronary angiography, whose symptoms were ultimately attributed to HAP.

### 1. Case Presentation

A 45-year-old male who is working as a soldier at a high altitude Siachen (~5500 meters above sea level) for over 12 months presented with atypical chest pain of several months duration. The pain was intermittent, non-exertional, and not related to food or posture.

The patient also reported occasional dizziness and shortness of breath, particularly after physical exertion.

He denied significant cardiovascular risk factors, including smoking or hypertension, and had no personal history of coronary artery disease.


### 2. Physical Examination

BP: 110/80 mmHg, HR: 50 bpm, regular, SpO<sub>2</sub> 95% on room air. Systemic examination revealed normal cardiovascular and respiratory findings

**Laboratory Investigations:** Hemoglobin: 19.5 g/dL (normal: 13-17 g/dL) Hematocrit: 58% (normal: 40-50%) ECG: Normal sinus rhythm, Bradycardia present

### 3. Clinical course:

Cardiology opinion obtained, 2D ECHO taken which showed Normal LV systolic function (LVEF -69%) and was not significant except for Bradycardia during study. CV doppler showed which showed significant stenosis or occlusions.



Graph 1: As per cardiologist advice TMT done

**Treadmill Test (TMT):** A stress test was conducted, which demonstrated significant ST-segment depression, consistent with inducible ischemia. The TMT results raised suspicion of coronary artery disease (CAD)

Test Details									
Protocol: Bruce		Pr.MHR: 174 bpm		THR: 156 (90 % of Pr.MHR) bpm					
Total Exec. Time: 12 m 2 s		Max. HR: 153 ( 88% of Pr.MHR )bpm		Max. Mets: 14.90					
Max. BP: 150 / 80 mmHg		Max. BP x HR: 22950 mmHg/min		Min. BP x HR: 3380 mmHg/min					
Test Termination Criteria:									
Protocol Details									
Stage Name	Stage Time (min : sec)	Mets	Speed (mph)	Grade (%)	Heart Rate (bpm)	Max. BP (mm/Hg)	Max. ST Level (mm)	Max. ST Slope (mV/s)	
Supine	0 : 43	1.0	0	0	42	120 / 80	0.42 aVR	0.71 II	
Standing	0 : 20	1.0	0	0	48	120 / 80	0.21 aVR	0.71 V1	
Hyperventilation	0 : 19	1.0	0	0	48	120 / 80	0.21 aVR	0.71 V1	
1	3 : 0	4.6	1.7	10	71	120 / 80	0.64 aVR	-1.06 I	
2	3 : 0	7.0	2.5	12	86	120 / 80	0.64 I	-1.06 I	
3	3 : 0	10.2	3.4	14	100	130 / 80	-2.34 V4	-2.12 II	
4	3 : 0	13.5	4.2	16	153	150 / 80	-4.67 V4	-2.83 V4	
Peak Ex	0 : 2	14.9	5	18	153	150 / 80	-3.40 V5	1.06 III	
Recovery(1)	1 : 0	1.8	1	0	92	150 / 80	-3.40 V6	2.48 V3	
Recovery(2)	1 : 0	1.0	0	0	82	150 / 80	-1.49 V4	2.48 V3	
Recovery(3)	1 : 0	1.0	0	0	75	150 / 80	-1.70 V6	1.06 V1	
Recovery(4)	0 : 47	1.0	0	0	74	150 / 80	-1.70 V4	1.06 V4	

### Interpretation

The patient exercised according to the Bruce protocol for 12 m 2 s achieving a work level of Max. METS : 14.90. Resting heart rate initially 42 bpm, rose to a max. heart rate of 153 ( 88% of Pr.MHR ) bpm. Resting blood Pressure 120 / 80 mmHg, rose to a maximum blood pressure of 150 / 80 mmHg.

TMT TEST IS POSITIVE FOR INDUCED ISCHEMIA.

Graph: 2 Further, coronary Angiography done to rule out ASVCD, atherosclerotic vascular coronary Disease.

**Coronary Angiography:** Surprisingly, coronary angiography showed normal coronary arteries, ruling out significant atherosclerosis or occlusion. Given these findings, the differential diagnoses were revisited.

CORONARY ANGIOGRAM REPORT			
HB	15.7 gm/dl	WEIGHT	KG
UREA	19 gms/dl	BP	90/60 mmHg
CREATINE	0.5 mgs/dl	HEARTRATE	47 BPM
BLOOD GROUP		BMI	
HBSAG		RBS	Mgs/dl
CONTRAST	: NON IONIC (VISI PAUQE 350)		
ACCESS SITE	: RIGHT RADIAL. 5F RADIAL SHEATH		
CATHETER	: TIG 3.5 ( 5 F)		
HEPARIN DOSE	: 2500 UNITS		
OTHER MEDICATION	: INJ. NTG 100 mcgs		
LMCA	- BIFURCATES, NORMAL		
LAD	- TYPE III VESSEL, NORMAL, SLOW FLOW IN MID LAD		
	DIAGONALS/SEPTALS -NORMAL		
LCX	- DOMINANT, NORMAL		
	OM -NORMAL		
RCA	- NON - DOMINANT, NORMAL		
	PDA/PLVB -NORMAL		
LV FUNCTION	- NORMAL LV SYSTOLIC FUNCTION (EF-69%)		
IMPRESSION	- NORMAL EPICARDIAL CORONARIES		
DIAGNOSIS	- CHEST PAIN UNDER EVALUATION / TMT POSITIVE / POLYCYTHEMIA		
	NORMAL LV SYSTOLIC FUNCTION		
	NORMAL EPICARDIAL CORONARIES		
ADVICE	- MEDICAL MANAGEMENT		

Figure:1



#### 4. Differential Diagnosis

1. **Microvascular angina:** Dysfunction of small coronary vessels.
2. **High-altitude polycythemia:** Increased blood viscosity impairing oxygen delivery and increasing cardiac workload.
3. **Coronary vasospasm:** Transient vasoconstriction of coronary vessels.
4. **Pulmonary hypertension:** Chronic hypoxia can lead to right heart strain.

#### 5. Discussion

The diagnosis of HAP was confirmed based on the elevated hemoglobin and hematocrit levels. The patient's symptoms were attributed to blood hyperviscosity and impaired oxygen delivery. The patient underwent therapeutic phlebotomy, reducing hematocrit to 50%. Low-dose aspirin was started to prevent thrombosis.

Supplemental oxygen Advised for use during sleep and exertion to alleviate hypoxia. Hydration Ensured to prevent hemoconcentration. Advised to move to a lower altitude to prevent recurrence.

**Outcome:** The patient experienced marked improvement in symptoms after treatment. A follow-up TMT was negative for ischemia, and hemoglobin levels were maintained through periodic phlebotomy and lifestyle adjustments.

This case highlights the diagnostic challenge posed by HAP presenting with atypical chest pain and a positive stress test. Although the TMT was indicative of ischemia, normal coronary arteries on angiography pointed toward alternative causes such as blood hyperviscosity. The reduced oxygen-carrying capacity due to HAP can mimic ischemic symptoms, underscoring the importance of considering this condition in high-altitude populations.

#### 6. Conclusion

Patients with high-altitude polycythemia may present with chest pain and ischemic-like symptoms despite normal coronary angiography. A multidisciplinary approach that includes hematologic, cardiologic, and respiratory evaluations is essential for appropriate diagnosis and management. This report emphasizes the importance of considering high-altitude polycythemia in patients with ischemic-like symptoms who reside at high elevations.

#### References:

- [1] Leon-Velarde, F., Maggiorini, M., Reeves, J. T., et al. (2005). "High Altitude Polycythemia." *High Altitude Medicine & Biology*, 6(2), 147-157. DOI:10.1089/ham.2005.6.147
- [2] Grover, R. F. (2014). "High Altitude and Coronary Artery Disease." *Circulation*, 129(9), 975-978. DOI:10.1161/CIRCULATIONAHA.113.007488
- [3] Gupta, A. K., Nagpal, N., and Bhattacharyya, S. (2012). "High-altitude polycythemia: Mechanisms, Diagnosis, and Treatment." *Indian Journal of Critical Care Medicine*, 16(4), 222-227. DOI:10.4103/0972-5229.106493
- [4] Luks, A. M., Swenson, E. R., and Bärtsch, P. (2017). "Chronic Mountain Sickness: Clinical Aspects and Management." *High Altitude Medicine & Biology*, 18(2), 61-69. DOI:10.1089/ham.2017.0031
- [5] Monge, C., and León-Velarde, F. (1991). "Chronic Mountain Sickness: A Review." *High Altitude Medicine & Biology*, 2(2), 389-403. DOI:10.1089/15270290152606678
- [6] Villafuerte, F. C., and Corante, N. (2016). "Chronic Mountain Sickness: Clinical Manifestations, Etiology, Management, and Treatment." *High Altitude Medicine & Biology*, 17(2), 61-69. DOI:10.1089/ham.2016.0031
- [7] West, J. B. (2004). "High-Altitude Medicine." *American Journal of Respiratory and Critical Care Medicine*, 170(12), 1405-1413. DOI:10.1164/rccm.200307-865OE
- [8] Aryal, N., Weatherall, M., and Bhatta, Y. K. (2006). "Coronary Artery Disease and the Development of High Altitude Pulmonary Edema." *Thorax*, 61(2), 132-136. DOI:10.1136/thx.2005.045799
- [9] Jha, A. K., and Dua, S. (2009). "High-Altitude Polycythemia and Its Impact on Cardiovascular System: An Overview." *Journal of the Indian Academy of Clinical Medicine*, 10(2), 146-152.
- [10] Hackett, P. H., and Roach, R. C. (2001). "High-Altitude Medicine: Cardiopulmonary Health at Altitude." *New England Journal of Medicine*, 345(2), 107-114. DOI:10.1056/NEJM200107123450206

- [11] Arias-Stella, J., and Kruger, H. (1974). "Pathology of High-Altitude Heart Disease: Insights from Polycythemia." *American Journal of Cardiology*, 34(6), 744-750. DOI:10.1016/0002-9149(74)90723-8
- [12] Richalet, J. P., and Rivera, M. (2019). "Adaptation to High Altitude and Health Risks of Chronic Hypoxia." *Physiological Reviews*, 99(1), 61-121. DOI:10.1152/physrev.00021.2018
- [13] Janssen, R. J., Swenson, E. R., and Luks, A. M. (2020). "Pathophysiology and Management of High-Altitude Polycythemia: Understanding Chronic Mountain Sickness." *Comprehensive Physiology*, 10(1), 289-317. DOI:10.1002/cphy.c190006
- [14] Groves, B. M., Reeves, J. T., Sutton, J. R., et al. (1993). "Operation Everest II: Elevated Cerebral Blood Flow in Acute Mountain Sickness." *Journal of Applied Physiology*, 74(2), 405-415. DOI:10.1152/jappl.1993.74.2.405
- [15] Kaelin, W. G., Ratcliffe, P. J., and Semenza, G. L. (2016). "Pathways for Oxygen Regulation and Sensing: Implications for High-Altitude Physiology." *Nature Reviews Molecular Cell Biology*, 17(11), 647-662. DOI:10.1038/nrm.2016.114